<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634162</url>
  </required_header>
  <id_info>
    <org_study_id>SMF-01</org_study_id>
    <nct_id>NCT04634162</nct_id>
  </id_info>
  <brief_title>PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment</brief_title>
  <acronym>SWAP-5</acronym>
  <official_title>Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment: The Switching Antiplatelet -5 (SWAP-5) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scott R. MacKenzie Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet&#xD;
      inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients&#xD;
      undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor&#xD;
      ticagrelor is commonly utilized, there is very limited data on the optimal approach for&#xD;
      switching between these therapies. The methodological approach for this assessment should&#xD;
      rely on comprehensive pharmacodynamics (PD) investigations aimed to assess levels of P2Y12&#xD;
      receptor inhibition, pharmacokinetic (PK) investigations to assess systemic levels of the&#xD;
      drug/drug metabolite, and mechanistic investigations by assessment of levels of P2Y12&#xD;
      receptor gene expression. The overarching aim of this investigation is to rule out a&#xD;
      drug-drug interaction when ticagrelor is administered prior to cangrelor infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet&#xD;
      inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients&#xD;
      undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor&#xD;
      ticagrelor is commonly utilized, there is very limited data on the optimal approach for&#xD;
      switching between these therapies. In particular, ruling out a drug-drug interaction (DDI) is&#xD;
      critical to this extent as the presence of a DDI would translate into reduced or abolished&#xD;
      antiplatelet effects exposing these acute patients to an increased thrombotic risk. Despite&#xD;
      the available evidence suggesting a lack of DDI with the use of ticagrelor in cangrelor&#xD;
      treated patients, most data derive from studies in which ticagrelor was given at the time of&#xD;
      initiation or during cangrelor infusion. To date, there is no data to fully rule out a DDI&#xD;
      when ticagrelor is given prior to starting cangrelor infusion. The need for such&#xD;
      investigation is underscored by the relatively high prevalence of pretreatment with&#xD;
      ticagrelor in acute settings. The methodological approach for this assessment should rely on&#xD;
      comprehensive pharmacodynamics (PD) investigations aimed to assess levels of P2Y12 receptor&#xD;
      inhibition, pharmacokinetic (PK) investigations to assess systemic levels of the drug/drug&#xD;
      metabolite, and mechanistic investigations by assessment of levels of P2Y12 receptor gene&#xD;
      expression. The overarching aim of this investigation is to rule out a DDI when ticagrelor is&#xD;
      administered prior to cangrelor infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The Switching Antiplatelet Therapy-5 (SWAP-5) study will be a prospective, randomized, double-blind, placebo controlled, cross-over PK and PD investigation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, research staff and laboratory personnel will be blinded to treatment assignments. Masking and randomization of medications (cangrelor and placebo) will be performed by our institutional research pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity measured by VerifyNow</measure>
    <time_frame>2 hours</time_frame>
    <description>The primary end point of the study will be the non-inferiority in P2Y12 reaction units (PRU) measured by VerifyNow after discontinuation of cangrelor vs. placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ticagrelor loading dose followed after 1 hour by placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Kengreal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with known coronary artery disease (defined as prior type I myocardial&#xD;
             infarction, coronary revascularization, percutaneous or surgical, or presence of at&#xD;
             least a 50% stenosis in any major epicardial vessel).&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  On aspirin 81mg/qd for at least 1 month&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel,&#xD;
             ticagrelor) in past 30 days&#xD;
&#xD;
          -  Known allergies to ticagrelor or cangrelor&#xD;
&#xD;
          -  Considered at high risk for bleeding&#xD;
&#xD;
          -  History of intracranial bleeding/hemorrhagic stroke&#xD;
&#xD;
          -  On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban,&#xD;
             apixaban, edoxoban) within past 30 days&#xD;
&#xD;
          -  Known platelet count &lt;80x106/mL&#xD;
&#xD;
          -  Known hemoglobin &lt;10 g/dL&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Known end stage renal disease on hemodialysis&#xD;
&#xD;
          -  Known severe hepatic dysfunction&#xD;
&#xD;
          -  Acute or severe bronchial asthma or upper airway obstruction.&#xD;
&#xD;
          -  Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker&#xD;
             protection.&#xD;
&#xD;
          -  Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction&#xD;
             with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin,&#xD;
             nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and&#xD;
             telithromizycin.&#xD;
&#xD;
          -  Pregnant females [women of childbearing age must use reliable birth control (i.e. oral&#xD;
             contraceptives) while participating in the study]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Franchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Franchi, MD</last_name>
    <phone>9042442092</phone>
    <email>francesco.franchi@jax.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Goosen</last_name>
    <phone>9042445617</phone>
    <email>andrea.goosen@jax.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Franchi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>cangrelor</keyword>
  <keyword>switching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share study data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

